BridgeBio Pharma (BBIO) to Release Quarterly Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $150.7110 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $75.85 on Wednesday. The company has a market cap of $14.62 billion, a P/E ratio of -18.15 and a beta of 1.13. The stock has a 50-day moving average of $75.70 and a two-hundred day moving average of $63.72. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94.

Insider Activity at BridgeBio Pharma

In related news, CAO Maricel Apuli sold 2,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $74.26, for a total value of $148,520.00. Following the transaction, the chief accounting officer directly owned 130,297 shares of the company’s stock, valued at $9,675,855.22. This trade represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Neil Kumar sold 40,000 shares of the business’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $71.94, for a total transaction of $2,877,600.00. Following the completion of the sale, the chief executive officer directly owned 695,686 shares of the company’s stock, valued at approximately $50,047,650.84. This trade represents a 5.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 178,167 shares of company stock valued at $12,923,052. 18.20% of the stock is owned by company insiders.

Institutional Trading of BridgeBio Pharma

Large investors have recently made changes to their positions in the company. Freestone Grove Partners LP grew its stake in BridgeBio Pharma by 33.9% during the 4th quarter. Freestone Grove Partners LP now owns 125,201 shares of the company’s stock worth $9,577,000 after buying an additional 31,732 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of BridgeBio Pharma by 36.1% in the fourth quarter. AQR Capital Management LLC now owns 134,517 shares of the company’s stock valued at $10,289,000 after acquiring an additional 35,690 shares during the period. Abel Hall LLC purchased a new position in shares of BridgeBio Pharma during the fourth quarter worth approximately $809,000. EFG International AG acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $6,749,000. Finally, Kovack Advisors Inc. acquired a new position in shares of BridgeBio Pharma in the 4th quarter valued at $788,000. 99.85% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BBIO shares. Morgan Stanley began coverage on shares of BridgeBio Pharma in a report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 target price on the stock. JPMorgan Chase & Co. increased their price objective on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Truist Financial boosted their target price on BridgeBio Pharma from $80.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Leerink Partners upped their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Finally, Barclays assumed coverage on BridgeBio Pharma in a research note on Wednesday, January 28th. They issued an “overweight” rating for the company. Twenty-two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average price target of $82.05.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.